LONDON (ShareCast) - (Sharecast News) - Commercial biotechnology company Allergy Therapeutics has seen "highly positive" top-line results from a recent phase two dose-ranging study on its grass-pollen induced seasonal allergic rhinitis drug.
With approximately 30% of the population of Europe and 25% of the US being allergic to grass pollen, Allergy was very encouraged by the results of its Grass Modified Allergen Tyrosine Absorbed MPL Phase II dose-ranging study, which met its primary endpoint of establishing a dose-response relationship and a Phase III dose.

Allergy's trial saw a significant increase in immunoglobulin results, highly consistent with the dose response observed for the primary endpoint and an excellent adherence to the short treatment course with more than 95% of patients receiving the target cumulative dose during six weekly subcutaneous injections.

The G205 trial was a multi-centre, double-blind, placebo-controlled study designed to explore the safety and response of different cumulative doses of Grass MATA and MPL with the objective to achieve a dose recommended for Phase III development.

Manuel Llobet, chief executive at Allergy Therapeutics, stated: "This study represents a major milestone in our path forward to a registered grass allergy product in Europe."

"Additionally, this brings us closer towards marketing authorisation in the estimated $2bn US allergy market, a significant opportunity where our product has the potential to be the first registered subcutaneous immunotherapy for the treatment of grass allergy," Llobet added.

As of 0900 BST, Allergy shares had climbed 8.37% ahead to 26.55p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE